Pages

▼
Showing posts with label Gross-to-Net Bubble. Show all posts
Showing posts with label Gross-to-Net Bubble. Show all posts
Tuesday, July 22, 2025

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access

›
It’s time for Drug Channels ’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes...
Tuesday, July 15, 2025

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

›
Is the gross-to-net bubble —the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and disc...
Tuesday, July 08, 2025

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market

›
The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dynamics. Bu...
Friday, June 20, 2025

Transparency vs. Reality: Troubling Lessons from PBM Disclosure Laws (rerun)

›
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, ...
Friday, April 04, 2025

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns (rerun)

›
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: PBM Industry Update: Trends, Challenges, and Wha...
Wednesday, March 05, 2025

Transparency vs. Reality: Troubling Lessons from PBM Disclosure Laws

›
Last week, President Trump signed yet another executive order , this time promising to make healthcare pricing more transparent. While thi...
Tuesday, January 28, 2025

Drug Channels News Roundup, January 2025: Mark Cuban Fixes Healthcare, Payers’ G2N Bubble, Pharmacists Rejoice, 340B Shenanigans, and 46Brooklyn vs. Mushrooms

›
Get ready to climb a Crisco-covered light pole ! DCI’s hometown Philadelphia Eagles are going to Super Bowl LIX! Go E-L-G-S-E-S! ( No, that...
Tuesday, January 07, 2025

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns

›
It's time for Drug Channels ’ annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs’ list prices grew ...
Tuesday, December 10, 2024

PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023—But Will Soon Start Deflating (rerun)

›
This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see ...
Monday, December 09, 2024

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

›
This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see ...
Tuesday, October 29, 2024

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

›
Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and tr...
Tuesday, October 22, 2024

The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions

›
Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. For 2023, discounted purchases under the 340B progr...
Tuesday, October 15, 2024

If Plan Sponsors Are So Unhappy with Their PBMs’ Transparency, Why Won’t They Change the Model?

›
A new survey of plan sponsors sheds light on their satisfaction with transparency at large and small pharmacy benefit managers (PBMs). As y...
Wednesday, October 09, 2024

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

›
As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolu...
Tuesday, October 01, 2024

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira (rerun with an FTC update)

›
This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholes...
Tuesday, September 24, 2024

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

›
Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Joh...
Wednesday, September 04, 2024

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

›
The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announ...
Tuesday, July 23, 2024

Gross-to-Net Bubble Update: 2023 Pricing Realities at 10 Top Drugmakers

›
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the followin...
Tuesday, July 16, 2024

PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023—But Will Soon Start Deflating

›
Last week, the Federal Trade Commission (FTC) released its interim report on pharmacy benefit managers (PBMs). The report’s unsubtle subtitl...
Wednesday, May 22, 2024

Why the IRA Will Encourage Part D Plans to Prefer High-List, High-Rebate Drugs (video)

›
In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences o...